WallStSmart
AZN

AstraZeneca PLC

NASDAQ: AZN · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$187.37
+1.17% today

Updated 2026-04-30

Market cap
$287.11B
P/E ratio
27.85
P/S ratio
4.89x
EPS (TTM)
$6.65
Dividend yield
—
52W range
$130 – $211
Volume
2.0M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

AstraZeneca PLC (AZN) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$187.37
Consensus
$102.67
-45.20%
2030 Target
$208.73
+11.40%
DCF
$214.51
+4.07% MoS
1 analysts:
1 Buy1 Hold0 Sell

Management guidance

No specific revenue targets or CAGR guidance found in recent CEO communications. Management has emphasized 'sector leading replacement power' to manage the 2030 patent cliff (Tagrisso expiration ~2028) and is focused on pipeline execution with recent Phase III wins in Ultomiris (IgAN), tozorakimab (COPD), and cell therapy expansion. No quantified revenue guidance beyond analyst consensus ranges.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$341.55
$86.5B Rev × 6.4x P/S
Base case (2030)
$208.73
$86.5B Rev × 4x P/S
Bear case (2030)
$132.82
$86.5B Rev × 2.4x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$45.8B$54.1B$58.7B$64.8B$69.0B$74.2B$80.1B$86.5B
Revenue growth—18.0%8.6%10.3%6.4%7.5%8.0%8.0%
EPS$3.82$4.59$3.52$5.25$5.91$6.50$7.15$7.85
P/S ratio———4.0x4.0x4.0x4.0x4.0x
Implied price———$170.78$170.78$189.75$208.73$208.73

Catalysts & risks

Growth catalysts
+ Ultomiris accelerated approval filing for IgAN (rare kidney disease with unmet need)
+ Tozorakimab Phase III success in COPD (two pivotal trials met endpoints; $5B+ peak sales potential per Citi)
+ Tagrisso patent expiration mitigation through pipeline (Enhertu, Imfinzi expansion, cell therapy investments)
+ Cell therapy manufacturing scale-up (new China investment, Virginia $191M grant for US facility)
+ Imfinzi expansion into liver cancer (breakthrough status, potential super-blockbuster positioning)
Key risks
- Tagrisso patent cliff in 2028 (~30-40% of oncology revenue at risk if no mitigation)
- China headwinds and pricing pressure in key markets (recent divestiture of Bengaluru facility suggests margin pressure)
- Delayed cancer trial data (offset by recent tozorakimab and Ultomiris wins, but execution risk remains)
- Regulatory approval uncertainty for pipeline candidates (Phase III data positive but not guaranteed FDA/EMA approval)
- Competitive pressure from Merck, GSK, BMY in oncology and GLP-1 markets

Methodology

AstraZeneca PLC's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 1 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 27, 2026.